10

Loading video...

Sam Stevenson

By Sam Stevenson

Associate News Editor

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


A Missouri judge on Friday approved Bayer’s $7.25 billion settlement of lawsuits alleging that its Roundup weedkiller causes cancer, potentially resolving litigation that has burdened the company for nearly a decade.

A June U.S. Supreme Court ruling made it harder to sue Monsanto, which makes Roundup and is owned by Bayer, over the absence of a cancer warning on the product, leaving those who reject the settlement with fewer legal options.

People exposed before February 17, 2026, may qualify if they have already been diagnosed with non-Hodgkin lymphoma, a type of blood cancer, or receive a diagnosis during the program’s 16-year coverage period.

Read More on News

Timothy Boyer, a St. Louis Circuit Court judge, found the agreement “fair, reasonable, and adequate.”

Monsanto denies liability and maintains that glyphosate does not cause cancer, while Bayer said the settlement does not include an admission of liability or wrongdoing.

On Saturday morning, Newsweek emailed Christopher Seeger, who represents current claimants, and Eric D. Holland, who represents future claimants, for comment on how the claims process will operate.

Bayer has also referred Newsweek to a statement announcing the settlement’s approval (Court grants final approval to Roundup class settlement). The company said any appeal would pause further payments into the settlement fund until the challenge had been resolved.

Bill Anderson, Bayer’s chief executive, called the approval “a decisive milestone” in the company’s effort to reduce the risks posed by pending and future Roundup litigation.

Newsweek emailed Bayer and Monsanto for further comment on Saturday morning.

File image: Bottles of Monsanto's Roundup are seen for sale June 19, 2018 at a retail store in Glendale, California.

...

Key Points

File image: The Bayer Pharma AG building stands on August 29, 2018 in Berlin, Germany.

...

Who Qualifies For The Roundup Settlement?

The class covers U.S. residents who encountered an eligible Roundup product before the cutoff date.

Compensation requires a qualifying non-Hodgkin lymphoma diagnosis, medical proof, identification, evidence of U.S. residency, and sufficient exposure information.

Those without cancer remain within the future-claim structure.

They can apply if diagnosed before the sixteenth annual payment date; anyone still unaffected then is released from the agreement without receiving money.

Claims are divided between occupational and residential users.

Occupational status generally requires more than 80 hours of workplace exposure in agriculture, industry, turf or ornamental work, plus earned income from that role exceeding either half of total income or $15,000 in at least one year.

Everyone else who satisfies the requirements is treated as residential.

Roundup weed killer is shown on May 14, 2019 in Chicago, Illinois.

...

How Much Could A Claimant Receive?

Nine tiers determine the starting value. The highest average, $165,000, applies to an occupational claimant diagnosed before 60 with an aggressive lymphoma subtype.

The lowest, $10,000, covers anyone diagnosed at 78 or older.

Other brackets account for age, whether the disease is aggressive or indolent and whether exposure occurred at home or through employment.

An allocation special master then adjusts the figure using the quality of exposure evidence, duration of contact, treatment intensity, cancer stage, and specified medical conditions.

Medical or governmental liens may reduce the amount reaching the claimant because Medicare, insurers or other payors can assert reimbursement rights.

How Will People Make A Claim?

Applicants will use a secure settlement portal operated by administrator BrownGreer PLC.

Submissions can begin after final approval, but payment cannot occur until the judgment becomes effective following any appeals.

A complete package must include the claim form, diagnosis records, exposure proof and required releases.

The administrator ordinarily has 30 days to check completeness, followed by another 30 days to decide eligibility; future claimants face an additional two-year wait before their eligibility date.

Quick-pay awards receive priority. Standard awards are processed by tier and then in eligibility-date order, meaning acceptance does not guarantee immediate disbursement if the annual fund has been exhausted.

Can People Who Previously Settled Qualify?

The agreement does not provide a simple yes-or-no rule for everyone who previously reached an arrangement with Monsanto Company.

For people diagnosed before the settlement, some earlier written agreements with Monsanto Company could be taken into account when their payout is calculated.

Anyone who previously settled a Roundup claim or signed a release should check whether that agreement prevents them from seeking further compensation under the new settlement.

What Happens To People Who Opted Out?

The exclusion deadline was June 4.

A valid opt-out receives no settlement benefit and is not bound by the approval judgment, preserving the ability to pursue an individual case subject to applicable defenses.

That route now carries additional risk. In June, the U.S. Supreme Court ruled 7-2 that federal pesticide law barred state-law failure-to-warn claims in John Durnell’s case, removing an important avenue used by Roundup plaintiffs.

Why Some Roundup Cancer Victims Opposed The $7.25 Billion Deal

Objectors argued that proposed awards were too small compared with amounts received through previous settlements.

Boyer rejected that challenge, reasoning that more delay could leave seriously ill people, including terminal cancer patients, waiting “an indeterminate number of years.”

Seeger said the Supreme Court decision had narrowed victims’ options and that supporters wanted compensation delivered as quickly as possible.

Newsweek’s reporters and editors used Martyn, our AI assistant, to produce this story. Learn more about Martyn here.

Contact Newsweek editor on this story: Edward Pearcey.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines